As a major participant in the largest protein biomarker study of its kind, Myriad RBM will analyze more than 8,000 samples for Sanofi Aventis’ Outcome Reduction with Initial Glargine Intervention (ORIGIN) project, a pre- and early diabetes clinical study. The goal of the collaboration is to identify biomarker profiles that optimize treatment and improve care for diabetes patients. The research will be done using an expanded version of Myriad RBM’s DiscoveryMAP service and will provide quantitative measurement of nearly 300 blood-based proteins. The Population Health Research Institute (PHRI) managed the ORIGIN trial and is contributing samples and guiding data analysis to link biomarker measurements to clinical outcomes.